CRISPR Therapeutics AG (CRSP) Long-Term Investments (2016 - 2025)

CRISPR Therapeutics AG has disclosed Long-Term Investments across 5 years of filings, most recently posting $28.4 million for Q3 2025.

• In Q3 2025, Long-Term Investments changed N/A year-over-year to $28.4 million; the TTM figure through Sep 2025 stood at $28.4 million (changed N/A YoY), while the FY2023 annual figure was $2.0 million, down 96.24% from the prior year.
• Long-Term Investments came in at $28.4 million for Q3 2025 at CRISPR Therapeutics AG, up from $11.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $77.1 million in Q3 2022 to a low of $2.0 million in Q4 2023.
• Average Long-Term Investments over 4 years is $23.9 million, with a median of $9.8 million recorded in 2022.
• Year-over-year, Long-Term Investments tumbled 96.24% in 2023 and surged 128.85% in 2024.
• Over 4 years, Long-Term Investments stood at $53.1 million in 2022, then tumbled by 96.24% to $2.0 million in 2023, then surged by 460.8% to $11.2 million in 2024, then soared by 153.32% to $28.4 million in 2025.
• Per Business Quant data, the three most recent Long-Term Investments figures were $28.4 million in Q3 2025, $11.2 million in Q2 2024, and $2.0 million in Q4 2023.